IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses.
|
31054420 |
2019 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
Biomarker |
BEFREE |
In univariable analyses, mutated ATM (P < 0·001), NOTCH1 (P < 0·001) and SF3B1 (P = 0·002) as well as unmutated IGHV (P < 0·001), del(11q) (P < 0·001) and trisomy 12 (P < 0·001) by hierarchal FISH and advanced Rai (P = 0·05) and Binet (P < 0·001) stages were associated with shorter TTFT.
|
31243771 |
2019 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
Biomarker |
BEFREE |
IGHV status did not influence clinical outcomes in trisomy 12 CLL.
|
28641468 |
2018 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
Clinical and biological associations were determined including NOTCH1 mutations with advanced stage (Binet stage, P = 0.010), unmutated immunoglobulin heavy-chain variable region (IGHV) gene (P < 0.001) and trisomy 12 (+12) (P = 0.014).
|
29573199 |
2018 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
Del(17)(p13.1) predicted shorter PFS and OS (p < 0.0001 for each), as did del(11q)(22.3) (p < 0.0001, p = 0.005, respectively), trisomy 12 with mutated Notch1 (p = 0.003, p = 0.03, respectively) and unmutated IGHV (p = 0.009, p = 0.002, respectively), all relative to patients without these features.
|
25721902 |
2015 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
BIRC3 mutations (2.5%) were associated with unmutated IGHV genes (U-CLL), del(11q) and trisomy 12, whereas MYD88 mutations (2.2%) were exclusively found among M-CLL.
|
24943832 |
2015 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
AlteredExpression |
BEFREE |
High IGF1R gene expression was significantly associated with IGHV unmutated (IGHV-UM) status (p<0.0001), high CD38 expression (p<0.0001), trisomy 12 (p<0.0001), and del(11)(q23) (p=0.014).
|
25786252 |
2015 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
We also identified miRNAs whose expression was distinctive of cases with mutated versus unmutated IGHV genes or cases with 13q, 11q, and 17p deletions and trisomy 12.
|
24916701 |
2014 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
GeneticVariation |
BEFREE |
In the CLL cases, the IGH/BCL2 fusion was remarkably associated with trisomy 12 (13/22) and mutated IGHV status (20/21) and did not affect the outcome.
|
22686190 |
2012 |
IGHV3OR16-7
|
Trisomy 12
|
0.100 |
Biomarker |
BEFREE |
In contrast, B-CLL cases with trisomy 12 lacking trisomy 19 mostly had unmutated IGHV genes.
|
17593029 |
2007 |